Fundraising FoxMesintel Therapeutics
1 known investors
Find your way into Mesintel Therapeutics
Sign up to see every warm intro you have to Mesintel Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mesintel Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mesintel develops a proprietary target discovery platform based on fibroblast biology to accelerate drug development in cancer, fibrosis, rare diseases, tissue regeneration, and aging-related conditions. The company uses single-cell multi-omics, genetically engineered models, and AI/ML to identify novel therapeutic targets.
Founders & leadership
Investors · 1
Frequently asked questions
- What does Mesintel Therapeutics do?
- Mesintel develops a proprietary target discovery platform based on fibroblast biology to accelerate drug development in cancer, fibrosis, rare diseases, tissue regeneration, and aging-related conditions. The company uses single-cell multi-omics, genetically engineered models, and AI/ML to identify novel therapeutic targets.
- Who founded Mesintel Therapeutics?
- Mesintel Therapeutics was founded by T. Michael Underhill, Lesley Hill, R. Wilder Scott, Jonathon Jafari.
- Who are Mesintel Therapeutics's investors?
- Mesintel Therapeutics's investors include Innovation UBC.